Quick Comparison
| Semax | Selank | |
|---|---|---|
| Parent molecule | Fragment of ACTH(4-10) | Analog of tuftsin |
| Primary research focus | Cognitive enhancement, focus, neuroprotection | Anxiolytic (anti-anxiety) effects, mood regulation |
| Proposed mechanism | Increased BDNF expression, dopaminergic and serotonergic modulation | GABAergic signaling, enkephalinase inhibition, some BDNF influence |
| Russian clinical history | Previously marketed as a nasal spray for stroke recovery and cognitive impairment | Previously marketed as nasal drops for anxiety |
| Current US status | Sold only as a research chemical | Sold only as a research chemical |
What Each Compound Is
Semax is a synthetic peptide analog of ACTH(4-10), a short fragment of adrenocorticotropic hormone. It was engineered to retain that fragment's neurological activity while removing the hormonal, adrenal-stimulating activity of full-length ACTH. Semax has a documented history of use in Russia, where it was marketed as a nasal spray for conditions like stroke recovery and cognitive impairment. In the peptide research community today, it's studied mainly for cognitive enhancement, focus, and neuroprotection.
Selank is a synthetic analog of tuftsin, a naturally occurring immunomodulatory peptide fragment. It's studied primarily for anxiolytic effects, meaning anti-anxiety effects, without the sedation associated with traditional anti-anxiety medications. Selank also has some research interest in immune modulation, a nod to tuftsin's original immunological role. Like Semax, it was previously registered and marketed in Russia as a pharmaceutical, in Selank's case as nasal drops for anxiety.
Mechanism: Cognition vs Calm
Semax's proposed mechanisms center on increased BDNF (brain-derived neurotrophic factor) expression along with modulation of the dopaminergic and serotonergic systems, pathways associated with focus, memory, and neuroprotection. This lines up with its research history around stroke recovery and cognitive impairment.
Selank's proposed mechanisms are different in emphasis. Research points to effects on GABAergic signaling, along with inhibition of enkephalin-degrading enzymes, which may prolong the activity of the body's own opioid-like calming peptides. Selank also has some documented influence on BDNF expression, an area of overlap with Semax, even though the two compounds are generally positioned for different purposes.
Why this matters: Semax is generally positioned as a cognitive and neuroprotective compound, while Selank is generally positioned as an anxiolytic and mood-regulation compound. They share some neurotrophic pathway overlap through BDNF, but that overlap doesn't make them interchangeable.
Human and Preclinical Evidence
Both Semax and Selank were developed and studied extensively in Russia, where each has a longer clinical-use history than in the US. Semax's Russian research base centers on stroke recovery and cognitive impairment, consistent with its nasal-spray registration there. Selank's Russian research base centers on anxiolytic use, consistent with its own history as a registered pharmaceutical for anxiety.
In the US, neither compound has gone through the FDA drug-approval process, and current research interest in the wider peptide community reflects each compound's original Russian research focus, cognition and neuroprotection for Semax, anxiety and mood regulation for Selank.
Regulatory Status and Safety
Both Semax and Selank are currently sold in the US as research chemicals for laboratory research use only, not as FDA-approved prescription products, despite each having a prior history of pharmaceutical registration in Russia. That earlier registration doesn't carry over to US regulatory status. Neither compound should be treated as over-the-counter or prescription-equivalent based on its Russian history. As with any peptide, a general safety baseline before starting a protocol is standard practice, see the bloodwork section below.
What They Have in Common, and What's Different
In common: both are synthetic peptides developed and first studied in Russia, both were previously registered there as nasal pharmaceutical products, both are currently sold in the US only as research chemicals, and both have some documented influence on BDNF expression.
Different: the parent molecule each is derived from (an ACTH fragment for Semax, a tuftsin analog for Selank), the primary research focus of each (cognition and neuroprotection for Semax, anxiolytic and mood effects for Selank), and the specific signaling pathways each is studied through beyond their shared BDNF overlap.
Bloodwork to Track
Unlike some other peptide comparisons, there isn't a single standard clinical bloodwork marker that tracks Semax or Selank's effects. Neither compound moves a specific hormone level the way growth hormone secretagogues move IGF-1, so there's no dedicated biomarker to point to here. What's still worth doing before starting either one is a general baseline safety panel: a comprehensive metabolic panel and a CBC. See the full peptide bloodwork guide for what a baseline panel typically covers before starting any new peptide protocol.
Choosing Between Them
This isn't really an either-or decision, it's a question of what problem is being addressed. Semax fits a goal centered on focus, cognitive performance, or neuroprotection. Selank fits a goal centered on calm and mood regulation without sedation. Some people in the research community use them together for complementary reasons rather than choosing one over the other. BioStackIQ's Rate My Stack can score a stack that includes either or both against BioStackIQ's optimization categories, and Build Protocol can help lay out dosing and timing once a direction is chosen.